The Benefits of Exercise for Substance Use Disorders.

Published Date: 06 May 2023

According to recent research, physical activity is a "promising" intervention for substance use disorders.

Read Full News

Todays Updates


FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson


argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits Marco Meglio


Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy Isabella Ciccone, MPH


The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome Louie Pasculli


A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.

Personalized Care Improvements Identified for Older Patients with Skin Cancer


Personalized Care Improvements Identified for Older Patients with Skin Cancer

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc


New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

What to Expect at the 2026 Maui Derm Conference


What to Expect at the 2026 Maui Derm Conference

Todays Updates


FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson


argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits Marco Meglio


Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy Isabella Ciccone, MPH


The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome Louie Pasculli


A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.

Personalized Care Improvements Identified for Older Patients with Skin Cancer


Personalized Care Improvements Identified for Older Patients with Skin Cancer

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc


New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

What to Expect at the 2026 Maui Derm Conference


What to Expect at the 2026 Maui Derm Conference

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

2.

The Benefits of Exercise for Substance Use Disorders.

3.

Microplastics can cause malignant changes in lung cells

4.

Medical Journal March 29, 2023

5.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot